Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 60

1.

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES) - first results from PathIES.

Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJ, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JM, Bliss JM, Coombes RC; PathIES Sub-Committee.

Ann Oncol. 2015 May 22. pii: mdv242. [Epub ahead of print]

PMID:
26002610
2.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients: Results of an open-label, randomized, controlled phase II study (CERTO).

Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K.

Ann Oncol. 2015 May 4. pii: mdv219. [Epub ahead of print]

PMID:
25939894
3.

Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.

Xu Q, Surendran N, Verhoeven D, Klapa J, Ochs M, Pichichero ME.

Vaccine. 2015 Feb 18;33(8):993-1000. doi: 10.1016/j.vaccine.2015.01.014. Epub 2015 Jan 15.

PMID:
25597944
4.

Divergent mucosal and systemic responses in children in response to acute otitis media.

Verhoeven D, Pichichero ME.

Clin Exp Immunol. 2014 Oct;178(1):94-101. doi: 10.1111/cei.12389.

PMID:
24889648
5.
6.
7.

Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model.

Verhoeven D, Xu Q, Pichichero ME.

Vaccine. 2014 May 30;32(26):3205-10. doi: 10.1016/j.vaccine.2014.04.004. Epub 2014 Apr 13.

PMID:
24731814
8.

Enhanced innate antiviral gene expression, IFN-α, and cytolytic responses are predictive of mucosal immune recovery during simian immunodeficiency virus infection.

Verhoeven D, George MD, Hu W, Dang AT, Smit-McBride Z, Reay E, Macal M, Fenton A, Sankaran-Walters S, Dandekar S.

J Immunol. 2014 Apr 1;192(7):3308-18. doi: 10.4049/jimmunol.1302415. Epub 2014 Mar 7.

9.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team.

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

PMID:
24331154
10.

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M.

J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.

11.

Lower nasopharyngeal epithelial cell repair and diminished innate inflammation responses contribute to the onset of acute otitis media in otitis-prone children.

Verhoeven D, Nesselbush M, Pichichero ME.

Med Microbiol Immunol. 2013 Aug;202(4):295-302. doi: 10.1007/s00430-013-0293-2. Epub 2013 Apr 11.

12.

Chronic stress undermines the compensatory sleep efficiency increase in response to sleep restriction in adolescents.

Astill RG, Verhoeven D, Vijzelaar RL, Van Someren EJ.

J Sleep Res. 2013 Aug;22(4):373-9. doi: 10.1111/jsr.12032. Epub 2013 Feb 9.

13.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

Garnett SA, Martin M, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Lindemann JP, Di Leo A.

Breast Cancer Res Treat. 2013 Feb;138(1):149-55. doi: 10.1007/s10549-012-2395-8. Epub 2013 Feb 3.

14.

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP.

Ann Oncol. 2012 Oct;23(10):2663-70. Epub 2012 Apr 3.

15.

Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling.

Pahl JH, Verhoeven DH, Kwappenberg KM, Vellinga J, Lankester AC, van Tol MJ, Schilham MW.

Mol Immunol. 2012 May;51(1):91-100. doi: 10.1016/j.molimm.2012.02.119. Epub 2012 Mar 16.

PMID:
22424784
16.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; PEER investigators.

Ann Oncol. 2012 Aug;23(8):1986-92. Epub 2012 Mar 6.

17.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.

PMID:
22265698
18.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

19.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.

Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L.

BMC Cancer. 2010 Nov 23;10:642. doi: 10.1186/1471-2407-10-642.

20.

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M.

J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. Erratum in: J Clin Oncol. 2011 Jun 1;29(16):2293.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk